Ono Pharmaceutical

An artists 3D rendering of cancerous blood cells among healthy red blood cells The cells fill the image and are of various
Biotech

Ono pays $280M upfront for Ionis' phase 2 blood cancer med

Japan's Ono Pharmaceutical is paying $280 million to acquire Ionis’ phase 2-stage antisense oligonucleotide for a rare type of blood cancer.
James Waldron Mar 12, 2025 6:30am
An imaginary winners podium is modelled and rendered

Merck KGaA tumor trial hits goal, teeing up Daiichi, Ono rivalry

Nov 12, 2024 4:46am
Graphic image of two hands shaking with employeesexecutives on the forearms of each shaking hand

Ono inks $700M biobuck deal to bag preclinical LigaChem ADC

Oct 10, 2024 9:40am
pivot change turnaround direction walk away

Shattuck axes CD47 program, cuts 40% of staff over weak data

Oct 1, 2024 8:22am
A series of dice with a bag on them illustrating cost cuts

Cue lays off 25%, prioritizing preclinical autoimmune assets

Jul 26, 2024 4:29am
Graphic image of a cardboard box delivered to a doorstep with a welcome mat

Equillium delivers new lupus data to Ono's doorstep

Apr 1, 2024 10:53am